Hypoglycemia News and Research RSS Feed - Hypoglycemia News and Research

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.
American Diabetes Association issues statement to address diabetes management in LTC facilities

American Diabetes Association issues statement to address diabetes management in LTC facilities

The care of adults over age 65 with type 2 diabetes is a growing concern: the prevalence of diabetes is highest in this age group and is expected to grow as the U.S. population ages, with many needing care at long-term care (LTC) facilities. [More]
Use of antenatal steroids during late preterm delivery prevents neonatal respiratory complications

Use of antenatal steroids during late preterm delivery prevents neonatal respiratory complications

In a study to be presented on Feb. 4 in the oral plenary session at 8 a.m. EST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in Atlanta, researchers with the Eunice Kennedy Shriver National Institute of Child Health and Human Development and Maternal-Fetal Medicine Units Network found that the administration of antenatal steroids in pregnancies at risk for late preterm delivery prevents respiratory and other neonatal complications. [More]
Nearly 3.3 million children in U.S. have dizziness or balance problem

Nearly 3.3 million children in U.S. have dizziness or balance problem

More than 1 in 20 (nearly 3.3 million) children between the ages of 3 and 17 have a dizziness or balance problem, according to an analysis of the first large-scale, nationally representative survey of these problems in U.S. children. [More]
Lilly receives FDA approval for Humulin R U-500 KwikPen

Lilly receives FDA approval for Humulin R U-500 KwikPen

The U.S. Food and Drug Administration has approved Eli Lilly and Company's Humulin R U-500 KwikPen(insulin human injection) 500 units/mL, a pre-filled device containing Humulin R U-500, a highly concentrated formulation of insulin. [More]
UVA-developed artificial pancreas system to undergo final testing in two clinical trials

UVA-developed artificial pancreas system to undergo final testing in two clinical trials

A device developed by University of Virginia School of Medicine researchers to automatically monitor and regulate blood-sugar levels in people with type 1 diabetes will undergo final testing in two clinical trials beginning in early 2016. [More]
Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Researchers will soon undertake one of the largest-ever long-term clinical trials of a system designed to help regulate blood sugar levels of individuals with type 1 diabetes mellitus. If the so-called artificial pancreas system performs in patients as hoped, it could lead to commercial trials and eventual regulatory approval in the United States and abroad. [More]
Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. [More]
Mayo Clinic researchers report national trend toward overtesting HbA1C levels in diabetes patients

Mayo Clinic researchers report national trend toward overtesting HbA1C levels in diabetes patients

In a study released online today in The BMJ, researchers from Mayo Clinic report a national trend toward overtesting glycated hemoglobin (HbA1C) levels in adult patients with Type 2 diabetes. [More]
Researchers begin landmark clinical study to restore normal insulin secretion in people with type 1 diabetes

Researchers begin landmark clinical study to restore normal insulin secretion in people with type 1 diabetes

Investigators at Montreal's Lady Davis Institute at the Jewish General Hospital and McGill University Health Centre have announced the start of a landmark clinical study aimed at restoring normal insulin secretion in people with longstanding type 1 diabetes. [More]
Researchers explore effects of hypoglycemia on cardiovascular autonomic control

Researchers explore effects of hypoglycemia on cardiovascular autonomic control

Past studies have shown an association between strict control of blood sugar and increased mortality. These studies have also suggested that a consequence of this strict control is low blood sugar (called hypoglycemia), which may have adverse effects on the heart. [More]
Pharmacy-led glycemic control program improves outcomes for surgical patients with diabetes

Pharmacy-led glycemic control program improves outcomes for surgical patients with diabetes

A pharmacy-led glycemic control program is linked to improved outcomes for surgical patients with diabetes and those who develop stress-induced hyperglycemia or high blood sugars as a result of surgery, according to a new Kaiser Permanente study published in the American Journal of Pharmacy Benefits. [More]
Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. [More]
Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that Synjardy (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States. [More]
Lilly acquires worldwide rights to intranasal glucagon from Locemia

Lilly acquires worldwide rights to intranasal glucagon from Locemia

Eli Lilly and Company and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia's intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. Intranasal glucagon, which is currently in Phase III clinical trial testing, could be the first needle-free rescue treatment for severe hypoglycemia. [More]
Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus. [More]
Vaccination against type 1 diabetes may soon be available to young children

Vaccination against type 1 diabetes may soon be available to young children

A vaccination against type 1 diabetes will soon also be available to young children: the Pre-POINTearly vaccination study will involve children between the ages of six months and two years from across Germany who have a first-degree relative with type 1 diabetes. [More]
Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours. [More]
IUPUI awarded grant to develop breathalyzer-type device for detecting hypoglycemia in diabetes people

IUPUI awarded grant to develop breathalyzer-type device for detecting hypoglycemia in diabetes people

A multidisciplinary team of researchers at Indiana University-Purdue University Indianapolis has been awarded a $738,000 National Science Foundation grant to develop a breathalyzer-type device to detect the onset of hypoglycemia, or low blood sugar episodes, in people with diabetes. [More]
Mitochondrial Pyruvate Carrier could potentially be a new drug target to treat diabetes

Mitochondrial Pyruvate Carrier could potentially be a new drug target to treat diabetes

High blood sugar is a defining characteristic of Type 2 diabetes and the cause of many of the condition's complications, including kidney failure, heart disease, and blindness. Most diabetes medications aim to maintain normal blood sugar (glucose) levels and prevent high blood sugar by controlling insulin. [More]
Researchers examine relationship between energy needs and 'pleasure' of eating in food intake

Researchers examine relationship between energy needs and 'pleasure' of eating in food intake

A team at the Laboratoire biologie fonctionnelle et adaptative (CNRS/Université Paris Diderot) investigated the relative role of energy needs and "pleasure" of eating in food intake. The researchers studied a group of neurons in mice. They observed that when the neuron activity is compromised, feeding behavior becomes less related to the body's metabolic needs and more dependent on food palatability. [More]
Advertisement